In this study, RNA sequencing of serum and tumor samples from patients receiving a combination of the IDO1 inhibitor linrodostat mesylate and nivolumab revealed that the composite of T-cell–inflamed and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression signatures correlated with treatment response. This evidence concerns the gene IDO1 and neoplasm.